Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer.

Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O.

Ann Surg. 2011 Dec;254(6):947-50. doi: 10.1097/SLA.0b013e3182382fd5.

PMID:
22107741
2.

Association of colorectal cancer and prostate cancer and impact of radiation therapy.

Huo D, Hetzel JT, Roy H, Rubin DT.

Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1979-85. doi: 10.1158/1055-9965.EPI-09-0241. Epub 2009 Jun 16.

3.

Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.

Nieder AM, Porter MP, Soloway MS.

J Urol. 2008 Nov;180(5):2005-9; discussion 2009-10. doi: 10.1016/j.juro.2008.07.038. Epub 2008 Sep 17.

PMID:
18801517
4.

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.

Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):342-8. doi: 10.1016/j.ijrobp.2009.02.011.

PMID:
20117287
5.
6.

Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.

Kendal WS, Eapen L, Macrae R, Malone S, Nicholas G.

Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):661-8. Epub 2006 Mar 20. Erratum in: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1294-5.

PMID:
16545920
7.

Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis.

Singh AK, Mashtare TL, McCloskey SA, Seixas-Mikelus SA, Kim HL, May KS.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1086-94. doi: 10.1016/j.ijrobp.2009.09.055. Epub 2010 Mar 28.

PMID:
20350797
8.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

9.

Cancer incidence after localized therapy for prostate cancer.

Moon K, Stukenborg GJ, Keim J, Theodorescu D.

Cancer. 2006 Sep 1;107(5):991-8.

10.

Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.

Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR; CaPSURE Investigators.

J Urol. 2007 Aug;178(2):529-34; discussion 534. Epub 2007 Jun 13.

PMID:
17570425
11.

Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.

Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM.

J Clin Oncol. 2011 Dec 1;29(34):4510-5. doi: 10.1200/JCO.2011.35.0991. Epub 2011 Oct 24.

PMID:
22025166
12.

Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma.

Bachaud JM, Berthier F, Soulié M, Malavaud B, Plante P, Rischmann P, Chevreau C, Daly-Schveitzer N, Grosclaude P.

Radiother Oncol. 1999 Feb;50(2):191-7.

PMID:
10368043
13.

Increased risk of colon cancer after external radiation therapy for prostate cancer.

Rapiti E, Fioretta G, Verkooijen HM, Zanetti R, Schmidlin F, Shubert H, Merglen A, Miralbell R, Bouchardy C.

Int J Cancer. 2008 Sep 1;123(5):1141-5. doi: 10.1002/ijc.23601.

14.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
15.

Sarcoma as a second malignancy after treatment for breast cancer.

Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M.

Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1231-7.

PMID:
11955733
16.

Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P.

Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047. Epub 2011 Jun 1.

PMID:
21664039
17.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

18.

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

Hamilton SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T, Lapointe V, Kahnamelli A, McKenzie M, Miller S, Morris WJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):934-41. doi: 10.1016/j.ijrobp.2014.07.032. Epub 2014 Sep 17.

PMID:
25240272
19.
20.

Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.

Abdel-Wahab M, Reis IM, Wu J, Duncan R.

Urology. 2009 Oct;74(4):866-71. doi: 10.1016/j.urology.2009.02.085. Epub 2009 Jul 22.

PMID:
19628258

Supplemental Content

Support Center